TAKE Solutions Limited
TAKE · NSE · Healthcare
StocksWizard rates TAKE Solutions Limited a Strong Sell, scoring 24/100 on our blended model. At ₹30.03 it trades above our blended DCF and relative-multiples fair value of ₹15.02, implying roughly 50% downside to that estimate — we read the stock as overvalued by 50%. Financial health scores 100/100 (grade A), in the safe band on the Altman Z-score, with a Piotroski F-score of 3/9. It clears 4 of 10 investability checks, with durability 61, valuation 0 and momentum 6 on our 0–100 scales.
These are StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹12.01. Low-confidence estimate — limited data.
Piotroski F-score 3/9 — quality of earnings & balance sheet.
Investability checklist
- ✓ROE above 15%16.5%
- –Low debt (D/E < 0.5)
- ✕Positive free cash flow
- –Revenue growth > 10%
- –Earnings growing
- ✓Net margin ≥ 10%20.0%
- ✓Current ratio > 1.54.54
- ✕Below our fair value
- ✕Margin of safety ≥ 20%
- ✕Above 200-day average
- ✕Above 50-day average
- –Positive 1-year return
- ✓Altman Z in safe zoneZ 86.17
- ✕Piotroski ≥ 73/9
1-year price
EOD · 2026-06-19Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Quarterly results
Annual financials
Shareholding
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
SWOT snapshot
Strengths
- •Healthy profit margin (20.0%).
- •Financially solid — Altman Z 86.17.
Weaknesses
- •Price below its 200-day moving average (downtrend).
- •Weak Piotroski score (3/9).
Opportunities
- •Well off its 52-week high — possible mean-reversion.
Threats
- •Rich valuation versus sector peers.
- •Trades ~50% above our estimated fair value.
About TAKE Solutions Limited
TAKE Solutions Limited, together with its subsidiaries, provides domain-intensive services in life sciences and software and information technology in India. The company offers clinical research, generics development, data sciences, regulatory affairs, and pharmacovigilance and safety services backed by technology expertise. It also provides embed digital and employ mobile solutions for patient centricity insight in life science sector; and payer solutions, including access t
More in Healthcare
All stocksOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.